Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
about
Which anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsPersistence and compliance with medication management in the treatment of overactive bladderPharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderTrospium chloride treatment of overactive bladderAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachSolifenacin significantly improves all symptoms of overactive bladder syndrome.The analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainMedical management of overactive bladderThe placebo effect in overactive bladder syndrome.Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study.Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Purinoceptors as therapeutic targets for lower urinary tract dysfunction.Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trialEfficacy and safety of propiverine in children with overactive bladder.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.Tolterodine for the treatment of overactive bladder: a review.Nocturia in relation to sleep, health, and medical treatment in the elderly.Role of muscarinic receptor antagonists in urgency and nocturia.Overactive bladder.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsThe role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.The emergence of new drugs for overactive bladder.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Developments in pharmacological therapy for the overactive bladder.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.Redefining response in overactive bladder syndrome.Overactive bladder pharmacotherapy: what does the future hold?A review of solifenacin in the treatment of urinary incontinence.Agents for treatment of overactive bladder: a therapeutic class review.Overactive bladder - 18 years - Part IIEfficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.Pharmacologic management of overactive bladder.Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.Tolterodine for the treatment of overactive bladder.
P2860
Q24203880-74BFCDC4-6824-4077-874F-EB510CE96D89Q24243870-A0DB4CBD-4E69-4B63-99A7-9B0F39F0FB42Q26765014-1CB614B1-F483-4371-A290-8F1F6EEFC32EQ28275473-D0FEF89D-8647-4416-862A-977EE2D4A3C4Q28308162-920AEB9E-FF61-4192-B15C-6B95F1C57CF6Q28742444-3750712F-3FDD-4A0E-8C5F-A5A056D5A8E3Q30445725-C1332230-A0E5-4C45-8452-4F1CEB678045Q30880978-8835CBF4-16C9-4456-81B6-627463A5ECFFQ33485538-C65DE3F2-2061-49AD-82BB-8EC6E6D334ECQ33515909-08F034D8-FFFB-4C55-B198-FC68A940B8E1Q33588346-819AC501-1A71-48BA-9BB0-BA107C595301Q34124065-0091B917-6480-46D8-AE38-07BBCFCCF81FQ34197411-D6E37834-11F2-4C4E-A653-3DF96B840C37Q34569114-A428C7EE-4EE1-4A6F-8FDC-072594228C83Q34900162-A44FFAB1-561C-4E88-8D12-51E8639D084CQ35042588-C3DC17B7-DF97-4FDA-A817-081296E5A4A8Q35419834-65E10CAE-A117-4DFB-B3AE-BE14ED568DE7Q35545723-277DA352-64F6-4A93-BB37-A7B76FF5016BQ35686738-2A54490C-97B2-4AA8-AC90-45997F2C1E75Q35903871-DB7E54C9-359C-482C-B2ED-9E742B76AECAQ36086072-5DD3DB9D-6225-43C3-85AC-EDCF4D9B7EF0Q36150735-10258122-8E07-44A6-BA36-AAD689B13DF5Q36219827-0E3872F6-F7BB-41AB-8DEF-E3F920246D73Q36219834-BB3834FC-67DB-4EDF-BF64-C272AF2981AEQ36226387-A40D198C-1395-4400-B769-F8CBF9B60723Q36307893-0A12BFD2-1B41-4627-AB90-FF5247D3F8FFQ36383267-3D96A1EE-0F7E-4A01-802C-7F17F5A40B6DQ36407417-F6C18554-5DC0-4F01-90FE-C186F26FB453Q36428471-CE7C9949-45D8-459A-A684-5FC5C357AB84Q36566857-801F9A00-DDE2-4267-B168-901332F80AD7Q36655193-E830F586-34B4-42D8-B430-254A90095A48Q36709649-AB0045D3-FF8F-4E4E-8192-0B0CB33CAD3DQ36815277-976056A7-EBD7-4FDB-A3D0-A9DEA81A4450Q36822864-83B1FB80-1E3E-437C-A63C-3366A558B8FEQ36885443-1E925DF4-B913-4872-B714-AF3A43A1298AQ36912766-6339319D-3AFB-4D70-809F-265A093646DFQ36919948-8553965E-8914-456F-8389-4FA01341E611Q37017434-87528FB2-7983-41C0-A73B-63859D013B7DQ37119868-F32CC0EE-1CD7-41F4-BDC3-63C08265523EQ37142090-B6CC5046-C66C-401E-86B0-1C011473CB0C
P2860
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Randomized, double-blind place ...... ymptomatic overactive bladder.
@en
Randomized, double-blind place ...... ymptomatic overactive bladder.
@nl
type
label
Randomized, double-blind place ...... ymptomatic overactive bladder.
@en
Randomized, double-blind place ...... ymptomatic overactive bladder.
@nl
prefLabel
Randomized, double-blind place ...... ymptomatic overactive bladder.
@en
Randomized, double-blind place ...... ymptomatic overactive bladder.
@nl
P2093
P2860
P1433
P1476
Randomized, double-blind place ...... ymptomatic overactive bladder.
@en
P2093
K Everaert
S Al-Shukri
T Rechberger
YM-905 Study Group
P2860
P304
P356
10.1111/J.1464-410X.2004.04606.X
P577
2004-02-01T00:00:00Z